Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN SODIUM versus POLYCILLIN PRB.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN SODIUM versus POLYCILLIN PRB.
AMPICILLIN SODIUM vs POLYCILLIN-PRB
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
POLYCILLIN-PRB combines ampicillin and probenecid. Ampicillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs). Probenecid inhibits renal tubular secretion of ampicillin, increasing its plasma concentration.
1-2 g IV/IM every 4-6 hours for serious infections; maximum 12 g/day.
250-500 mg orally every 6 hours or 500 mg-1 g intramuscularly every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life ~1 hour in healthy adults; prolonged to 2–5 hours in renal impairment (CrCl <10 mL/min) and up to 7–20 hours in anuria; neonatal half-life 2–4 hours.
Terminal elimination half-life: 1-1.5 hours in patients with normal renal function; prolonged to 7-10 hours in anuria.
Approximately 90% renal excretion via tubular secretion and glomerular filtration; small biliary excretion (<10%); fecal elimination negligible.
Renal: 60-80% unchanged via glomerular filtration and tubular secretion; Biliary/fecal: 20-40% as metabolites and unchanged drug.
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic